Jansen and Balls [43] first isolated chymopapain in 1941 from the latex of the Carica papaya fruit. Chemonucleolysis involves the use of chymopapain B, an injectable proteolytic enzyme, for the chemical dissolution of herniated nuclear material. Its mechanism of action is the hydrolysis of noncollagenous protein that interconnects long-chain mucopolysaccharide. The effects of the hydrolysis produced by chymopapain B are similar to those induced by corticosteroids. Chymopapain B also has neurolytic effects on the free nerve endings of the disc. This series of biochemical reactions [28, 39, 62, 63, 90] leads to the depolymerization of the nucleus pulposus, which lowers intradiscal pressure to relieve pain.
enrolled 17,000 patients to receive chymopapain injections in the United States and Canada during July 1975 [84] .
Controversy sparks market withdrawal
Controversy soon surrounded the new treatment, when a later study, conducted at the Walter Reed Army Medical Center in 1975, demonstrated no statistically significant difference in improvement between a placebo group and the experimental group, with success rates of 49% and 58%, respectively [82] . A subsequent critical analysis of the research design applied in the Walter Reed Medical Center's study found fault with the lack of an inert placebo, the insufficient dose of chymopapain, and the lack of technical expertise among the investigators, as well as other issues [12] . Physicians who were already treating intervertebral disc disease with the new substance, and obtaining excellent results, were disappointed to learn that the study at the Walter Reed Medical Center had prompted withdrawal of the FDA's approval for chymopapain use in humans. Chymopapain, however, remained in clinical use abroad -in Canada, Australia, and the UK.
Stymied by the lack of progress in regaining Federal approval, efforts were initiated to bypass the FDA through state legislature authorization. Illinois, Indiana, and Texas won the right to employ chymopapain in intervertebral disc treatment within each state. The papaya fruit is native to the state of Texas, and only Texas had a sufficiently favorable climate to allow its cultivation and, thus, extraction of the crude latex necessary for mass production of the drug. As a result, Chemolase was developed in Texas and legal use began in 1979.
The Texas trial
Between 1980 and 1982, 21 orthopedic surgeons and neurosurgeons enrolled 919 patients in a chymopapain postmarketing, open-label clinical trial. The Texas trial yielded an overall efficacy rate of 93%, and provided additional support for the safety and efficacy of chemonucleolysis in the treatment of low back pain and sciatica of discogenic origin following unsuccessful conservative management [85] .
Intradiscal injection of chymopapain produced 70 adverse reactions in 46 patients, or an overall complication rate of 5%. The most common side effect, erythema, occurred in 1.8% of the patient group. Anaphylaxis, the most serious reaction, occurred among 1.1% of the patients. Anaphylactic reactions that qualified as truly severe on the basis of individual physician assessment, however, were reported in only 0.54% of the patient population. Medical management of the anaphylaxis was successful in all patients without sequelae. Other reactions, which occurred at a similar rate, included giant urticaria, hypotension, and paraspinal or muscle spasms. Finally, back pain was reported in only 0.4% of the treated patients. No mortality was associated with the intradiscal application of chymopapain among the 919 enrolled study patients [85] .
Renewal of clinical testing
A new formulation of chymopapain, Chymodiactin, was introduced for clinical testing by Smith Laboratories in 1979 [66] . Chymodiactin was tested in 1981 in a randomized, double-blind, FDA-approved study of 108 patients. The clinical success rate was 82% among the Chymodiactin-treated patients; just 41% of the placebo group responded favorably. No complications resulted from this study.
An open study, conducted in Illinois among 1498 patients, yielded a 90% success rate [61] . Four cases of anaphylactic shock, however, produced death in two patients. One case of acute transverse myelitis also was reported, but no causal relationship between Chymodiactin and acute transverse myelitis could be established in an extensive follow-up study [83] . Chymodiactin was granted FDA approval in November 1982.
Of five major double-blind investigations conducted between 1975 and 1987, four trials provided statistically significant evidence in favor of chymopapain treatment. Success rates have ranged from 58% to 80% [18, 23, 25, 44, 82] . By pooling the results of the first three controlled trials, Haines [37] concluded that the "odds of successful outcome are 2.6 times as great with chymopapain as those after placebo injection." Until the 1990s, when reports of percutaneous laser therapy use in humans began to appear in the medical literature [10, 15] , chemonucleolysis stood alone as the only conservative treatment modality that could be applied prior to more invasive surgical interventions such as laminectomy, microdiscectomy, and percutaneous discectomy.
Indications
Chymopapain is indicated in the treatment of unremitting sciatica due to a proven herniated nucleus pulposus that has not responded, over a minimum period of 6 weeks, to the typical conservative measures: bed rest, exercise, antiinflammatory drugs, body corset, epidural blocks, physical therapy, and traction [84] . Due to its in vivo mode of action, chymopapain will only benefit the patient whose problem has been documented as being of discogenic origin.
Criteria for patient selection
The importance of patient selection as a key factor in the successful outcome of chemonucleolysis cannot be overemphasized. In a study conducted over 25 years ago, patients with severe sciatica of short duration experienced the best results from chymopapain injection. Patients who were obese, diabetic, or afflicted with a psychiatric illness showed the worst results [56] . Other research has examined the impact of pre-existing low back pain (LBP) versus no LBP on the outcome of chemonucleolysis. Those without LBP fared significantly better after the intervention than those already afflicted with LBP (85% success rate versus 52% success rate) [35] .
Only patients who have exhausted all conservative measures for sciatica of discogenic origin should be considered for chemonucleolysis. The patient's age also is important. In adults over the age of 60, the situation may often be that age-related degenerative changes have depleted the mucoprotein in the nucleus pulposus [13, 84] . Given this circumstance, the effectiveness of chymopapain would be diminished [3] . By itself, however, advanced age may not always preclude chymopapain treatment. Magnetic resonance imaging (MRI) studies have shown that even octogenarian patients can have normally hydrated discs, thus making them theoretically responsive to chemonucleolysis [84] .
Diagnosis of herniated nucleus pulposus should proceed with a complete medical history that includes known allergies, symptom history, total duration of back pain and of leg pain, location of sciatica, other significant medical history, and a listing of current medications. Neurologic and muscle testing also are pertinent to establishing a diagnosis. Testing of muscle strength, deep tendon reflexes, sensation, body mechanics, sciatic stretch, and straight leg raising in the seated and supine positions should be performed. The mechanical and sciatic stretch test should include sitting and supine straight leg raising, and tests for weakness, muscular atrophy, and dermatomal dysesthesia. By way of partial confirmation of the patient's complaints, the straight leg raising test should reproduce the patient's symptoms, as should the bowstring test and the ankle dorsiflexion test [3] . The importance of properly performing and recording these tests lies in the contribution they make to ascertaining the diagnosis of radiculopathy or sciatica, which is secondary to disc herniation -the only condition that warrants a chemonucleolysis procedure.
The ideal candidate should have only single-level disc involvement. Imaging and laboratory studies will aid in determining whether this is so, and should include routine radiographs of the lumbosacral spine, regular and enhanced computed tomography (CT) scans, MRI, myelography, discography, and electromyography. Findings of CT scans and myelography should correlate with the patient's signs, symptoms, and physical examination [3] .
Extreme care should be exercised in selecting candidates for chemonucleolysis. Judgment of the patient's suitability for this treatment must be based on complete evaluation of all the compiled subjective and objective data.
Contraindications

Absolute contraindications
A major and absolute contraindication for chymopapain use is allergic sensitivity to papain or papaya. Prior exposure to the chymopapain protein may have occurred from sources of papain that are commonly found in such commercial products as meat tenderizers, papaya fruit, beer, toothpaste, digestive aids, cosmetics, disinfecting solutions for contact lenses, laboratory reagents, and some treated leathers. About 1% of the world's population has the potential for reaction to the injectable form of chymopapain due to prior cross-reactive exposure [92] .
Skin testing or direct measurement of IgE antibodies through the radioallergosorbent (RAST) or fluorescent allergosorbent (FAST) tests can be useful in alerting the clinician to the patient's papain sensitivity. Nevertheless, even these tests cannot totally negate the possibility of an anaphylactic reaction, as there have been reports of allergic reactions triggered by epidermal injection for skin testing [55] . Such antigenic responses serve to underscore the importance of proper placement of the needle and localization of chymopapain to the nucleus pulposus [86] , which may decrease the probability of anaphylaxis.
Chymopapain treatment is intended strictly for the relief of radiculopathy secondary to a herniated disc. Clearly, if discography or MRI reveal a normal disc, then the need for chemonucleolysis is obviated. Work-up of the patient also must rule out a spinal cord tumor, disseminated malignancy, vertebral osteomyelitis, and disc space infection. Radiographic findings that point to conditions that would interfere with the process of chemonucleolysis, such as mechanical insufficiency, spinal stenosis, advanced spondylolisthesis, blockage by cervical or thoracic disc, inability to reach the disc space via the lateral approach, or intrathecal or intravascular flow of contrast dye upon discography, also would be contraindications to treatment with chymopapain [84] . Cauda equina syndrome, or any major, progressive neurologic condition, is another specific contraindication, because the response to chymopapain is time-dependent and may not offer prompt relief of the neural pressure produced in such urgent cases [67] . The absence of studies on the effects of chymopapain in pregnant women or upon fetal development makes pregnancy another absolute contraindication to chemonucleolysis.
Relative contraindications
There are several relative contraindications to chemonucleolysis that require careful consideration. Osteoarthritis may obstruct needle insertion. Any history of disc or vertebral infection becomes an important factor due to the potential for activating latent infection. Unsuccessful prior open discectomy may inhibit a favorable outcome due to the presence of fibrosis. Diabetes mellitus, especially with neuropathic changes, presents yet another relative contraindication. The anticipated success of chemonucleolysis could well be diminished by the extent and control of the diabetes. Other reported relative conditions have been medico-legal involvement, psychological problems, or inability to comprehend in English the description of the procedure and its potential outcomes [3, 68, 101] .
Operative technique
Preparation of the patient Chemonucleolysis may be performed by qualified orthopedic surgeons, neuro-radiologists, rheumatologists, neurologists, or similar specialists trained in needle placement procedures, in a facility with suitable radiologic capabilities, where proper sterile techniques can be carried out [84] . Fluoroscopic equipment (radiolucent table, C-arm fluoroscope with image intensifier, and equipment to take anteroposterior lateral X-ray films of the lumbar spine during the procedure) should be available. The procedure begins with presterilized instruments and takes place within a sterile environment.
The patient is placed on a radiolucent operating table in a left lateral decubitus position (Fig. 1) . Secure fastening of the patient with adhesive tape will avoid movement from a true lateral position. A portable C-arm fluoroscope is then placed over the stationary table, enabling the surgeon to have biplanar fluoroscopic control. The spine is properly centered; any curvatures can be corrected by a rolled towel placed in the flank above the iliac crest, and by rotating the hips, as needed. Proper positioning allows easier access to the lumbar disc. Both the lateral and anteroposterior views of the spine should be monitored.
The superior iliac spine, iliac crest, and the spinous process are located (Fig. 2 ) and identified using a marking pen. Measuring with a ruler, the area 8-10 cm lateral to the tip of the spinous process is marked. This mark is lined up with the intervertebral disc and will be the point of entry through the skin. Surgical preparation and draping of the patient follows.
Technical issues
Several technical considerations deserve attention. First, when the tips of the advancing needles reach a line adjoining the posterior borders of the vertebral bodies, the surgeon should obtain a firm, gritty sensation from the annulus. If the tip of the needle passes anterior to this line before this sensation is obtained, the needle will not bisect the disc, but will pass anteriorly and laterally to it (Fig. 3) . If this occurs, the needle should be reinserted at a more acute angle to the sagittal plane. To change the angle, the needle should first be withdrawn close to the skin beyond the lumbodorsal fascia.
There may be bony obstructions near the transverse process, the pars interarticularis, or the facet joint. These structures will be observable on a lateral projection with the C-arm. Obstruction at the level of the upper half of the vertebral body is likely due to the pars interarticularis. When opposite the disc space, the obstruction is probably due to the facet joint. If the transverse process causes obstruction of the L5-S1 disc, the insertion site for the needle is moved in a cephalad direction in order to reach the 195 Fig. 1 The patient is placed in the left lateral decubitis position with appropriate padding for comfort, and padding in the flank to help maintain the spine in a horizontal position Fig. 2 With the patient in the left lateral decubitus position and properly padded, it is possible to visualize spinal landmarks and their relationship to each other. Note, in particular, the posterior iliac spine, the iliac crest, and the spinous processes L4 intervertebral disc space. If either of the first two cases is true, the surgeon may angle the tip more posteriorly or anteriorly to gain access.
The angle of needle insertion, however, needs to be considered in conjunction with the overall size and shape of the patient. Having a clear, three-dimensional mental image of the lower lumbar region is important (Fig. 4) . It is also helpful to have an articulated spine specimen in the operating room.
For the L5 intervertebral disc space, the image intensifier is repositioned laterally. The L4 needle may serve as a landmark and guide to the position of the L5 disc space. The L5 needle is inserted at the same angle to the sagittal plane; that is, at 30°, but directed approximately 45°caudally. This angle is adjusted until the tip of the needle is level and adjacent to the posterior aspect of the vertebral bodies (the L5 disc space). In addition to radiographs, this is of great importance in assessing bony obstruction. Obstruction by the transverse process, for example, necessitates reducing the angle of the needle relative to the sagittal plane. There may be occasions when a broad transverse process at L5 obstructs this approach. If this occurs, the double-needle technique can be used: A 22-G needle is placed through an 18-G needle, with the tip of the 18-G needle lying just at the inferior level of the L5 vertebral body. By curving the distal half-inch of the 22-G needle with the bevel up, the needle will curve downward into the L5 intervertebral disc space as it passes out of the tip of the 18-G needle (Fig. 5, Fig. 6 ).
Once the surgeon has visually verified the correct needle tip placement with the aid of the C-arm image intensifier, a deionized, water-soluble contrast medium is injected. Resistance to flow will provide some indication regarding the integrity of the disc. The pattern outlined by the dye will give an indication of the morphology and continuity of the annulus.
Determining the integrity of the disc before chymopapain injection is important. The authors advocate the use of lumbar discography for this purpose. However, in the event that lumbar discography cannot be performed, the water acceptance test is an acceptable methodology for evaluating the integrity of the disc [3] .
To begin the lumbar discectomy, an amount of contrast medium adequate to fill the herniated disc is injected, usually 2.0-2.5 ml. An epidural leakage of the dye may occur, but this should not be regarded as a contraindication to chemonucleolysis. The procedure should be abandoned, however, in the rare instance that contrast dye leaks into the subdural or subarachnoid spaces. Resistance to the flow of contrast material is a reliable indicator of the integrity of the disc. A normal disc has a very high resistance to the flow. A prolapsed or herniated disc offers moderate resistance, whereas, a severely degenerated disc poses no resistance whatsoever. Coordination of flow resistance with visual monitoring of the dye allows the surgeon to assess the state of the disc. Radiograms in anteroposterior and lateral views are then taken. At least 10 min should elapse after injection of the dye for evaluation of a possible allergic response.
The amount of chymopapain injected depends on whether the herniation is contained, bulging or prolapsed; generally it should be no more than 1-2 cc. The injection should proceed slowly to allow adequate flow and binding of the enzyme. Three to five minutes after the injection, the needles may be removed. If no reaction occurs and all vital signs remain stable, the patient may be moved to the recovery room.
Complications
Prudent patient selection and correct technique are the most important elements for avoiding complications stemming from the injection of chymopapain. The most frequent complication is that of anaphylaxis, which may be prevented by prior sensitivity testing. The overall incidence of anaphylaxis has been estimated at 0.5%, or 1 out of every 200 patients. Males are slightly less likely to experience anaphylaxis than females (0.3% and 0.9%, respectively). African-American women, however, are at increased risk for anaphylaxis, with a reported incidence of 2.0%. Thus, sensitivity testing is especially indicated for those at increased risk owing to multiple allergies or gender-genetic attributes [3] .
The use of general anesthesia is associated with a minimally higher incidence of anaphylaxis (0.6%) over local anesthesia (0.4%) [3] . As the difference bears no statistical significance, however, both general and local analgesia may be used for performing chemonucleolysis [9] . Halogens, however, should be avoided, as they may sensitize the cardiac tissue to epinephrine and cause cardiac arrhythmia, and would preclude the use of epinephrine -the drug of choice for reversal of anaphylaxis [67] . Otherwise, each form of anesthesia brings distinct advantages to the chemonucleolysis procedure [67] . The most important caveat is to be fully prepared in the operating room for the management of anaphylactic shock, should it occur. Alexander presents a comprehensive treatment of this subject [3] .
Although anaphylaxis is still the most frequently reported adverse reaction associated with chymopapain, vascular and neurological complications can be equally serious and merit a watchful eye. Possible vascular events include cerebral aneurysm or arteriovenous malformation, intrathecal injection, cerebral accident, subarachnoid hemorrhage, post anti-coagulant, pheochromocytoma, and other vascular complications of unknown etiology. Complications of a neurological nature include acute transverse myelitis, cauda equina syndrome, Guillain-Barre syndrome, seizures, and other neurological complications of unknown etiology [67] .
The safety of chemonucleolysis was evaluated on the basis of 121 "serious" and "unexpected" adverse effects among 135,000 patients in the US reported to the Food and Drug Administration between 1982 and 1991. Seven cases of fatal anaphylaxis, 24 cases of infections, 32 cases of hemorrhage, 32 cases of complications of a neurologic nature (clinically expressed as paraplegia, paraparesis, hemiparesis, and foot drop), and 15 cases classified as "miscellaneous events" (cardiac and respiratory complications) were reported. The overall mortality rate was 0.019% [65] .
The account concluded that anaphylactic reactions were directly attributable to chymopapain, which is a known immunogen. Infections were the result of the lack of asepsis during the administration of the agent. Investigation of other adverse events did not yield any clear causality, but many were not considered likely to have resulted from chymopapain itself or to its administration [65] . This and similar reports serve to underscore the importance of careful patient selection and the attention to technique required to maximize the chances of a favorable outcome with chemonucleolysis [7] .
Pharmacology and toxicology
The work of Simmons and co-workers [86] with animal models helped to define the biochemical and toxicologic profile of chymopapain B (Chemolase) -especially with respect to the immunogenic reactions evoked by its intradiscal injection. Ensuing human clinical trials and clinical experience over more than a quarter of a century have served to further clarify the pharmacologic and toxicologic effects of this agent [25, 27, 30, 44] . Details of the metabolic process and the organic effects of chymopapain are provided in the report by Simmons and Nordby [84] . Borrowing from the work of Stem [91] , an overview of chymopapain toxicology follows. Toxicology occurs through the proteolysis of capillaries or the glycosaminoglycan (GAG) structure. Mortality may result from systemic effects such as petechial hemorrhage or emboli, or may be due to intrathecal invasion and the increase in cerebrospinal fluid pressure this produces.
Laser disc surgery versus chemonucleolysis
Reports of a new technique for treatment of sciatica caused by disc herniation have recently surfaced in the medical literature. Automated percutaneous lumbar discectomy utilizes yttrium aluminum garnet (YAG) lasers to lyze the herniated nucleus pulposus. French researchers designed a randomized, multicenter trial to compare this new therapeutic modality with chemonucleolysis. Of 141 patients, 69 were treated with percutaneous lumbar discectomy and 72 underwent treatment with chemonucleolysis. Within 6 months of treatment, 37% of the patients in the automated percutaneous discectomy group required open surgery, in marked contrast to only 7% in the chemonucleolysis group. Observation at 12 months indicated an overall success rate for the percutaneous lumbar discectomy group of 37%. Among those who had undergone chemonucleolysis, the success rate was 66%. Complications rates among both collectives were low, with the exception of postoperative low-back pain, which was experienced by 42% of the chemonucleolysis group [79] . In addition to the evaluation of a new therapy, this trial con- Another investigation compared YAG laser discectomy (percutaneous lumbar discectomy, PELD), chemonucleolysis (CN), and automated percutaneous lumbar discectomy (APLD). One hundred patients from the same hospital were assigned to each group (N=300). They were assessed at 1 year after surgery by means of physical examination, plain lumbosacral radiographs, CT and MRI studies, and a self-assessment questionnaire. Sixty-eight percent of the patients in the PELD group regarded their outcome as excellent or good; 23% considered their outcome as fair. In the CN group, the corresponding figures were 55% (excellent to good) and 27% (fair); among those in the APLD group, ratings were 48% (excellent to good) and 32% (fair). Nine percent of the patients in the PELD group subsequently underwent open microdiscectomy or continued to suffer from back pain with sciatica, compared with 18% in the CN group and 20% in the APLD group. Better extraction of the herniated mass was possible with PELD than with APLD. PELD also resulted in a lower rate of back pain and a smaller decrease in disc height than CN [54] .
Additional, controlled studies of these new therapies will be needed before they can be regarded as additional or replacement strategies in the treatment of sciatica associated with disc herniation. 
Open discectomy and microdiscectomy versus chemonucleolysis
In studies comparing chemonucleolysis to open discectomy, the mean success rate (with standard deviation) was 66%±17% as compared with 77%±13% for open surgery (Fig. 7) . In separately published studies, the mean success rate for chemonucleolysis was 74%±11% (Fig. 8) , with a mean of 77%±12% for open discectomy (Fig. 9) . When the two categories of reports were combined, the overall success rates were 72%±13% and 77%±12%, respectively. None of the standard deviations noted were statistically significant. The mean microdiscectomy success rate was higher, at 86%±9%, but nonetheless, this was not significantly different than the mean for the other procedures (Fig. 10) .
Conclusion
With more than 30 years of clinical use, chemonucleolysis has become established as a safe, effective procedure for the treatment of sciatica secondary to disc herniation. In comparisons of adverse effects associated with chymopapain injection and open discectomy, chemonucleolysis rates as the safer procedure by far [65] . Experience has shown that the only true complication is anaphylaxis, which can be predicted by sensitivity screening and controlled with appropriate treatment [3] . Thorough consideration of patient selection, widespread testing for immunogenic potential and scrupulous technique remain the key factors to the successful outcome of a chemonucleolysis procedure. chemonucleolysis in the treatment of sciatica: a prospective randomized trial. 
